MEG3, considering as an oncogenic lncRNA (Al-Rugeebah et al., 2019), is indicated to affect EMT in various cancer types such as breast cancer (Zhang et al., 2017), ovarian cancer (Wang et al., 2019), lung cancer (Terashima et al., 2017) and gastric cancer (Xu et al., 2018). Here, MEG3 is linked to breast cancer.